Acadia Pharmaceuticals vs Indivior
Add, change or remove companies; up to four.
The short version
- Indivior is the larger business, with $1.2B of revenue in fiscal 2025 against $1.1B for Acadia Pharmaceuticals.
- Acadia Pharmaceuticals grew revenue faster (11.9%, against 4.3%).
- Indivior kept more of each dollar of sales as operating profit (21.2% operating margin, against 9.8%).
- Acadia Pharmaceuticals turned more of its sales into free cash flow (9.8% FCF margin, against β7.5%).
- Investors pay more for each dollar of Indiviorβs earnings: a P/E of 12.4x against 8.8x for Acadia Pharmaceuticals.
| Latest fiscal year | ACAD Β· FY25 | INDV Β· FY25 |
|---|---|---|
| Size | ||
| Market cap | $3.4B | $4.3B |
| Revenue | $1.1B | $1.2B |
| Free cash flow | $105M | β$93.0M |
| Net income | $391M | $210M |
| Growth | ||
| Revenue growth | 11.9% | 4.3% |
| 5-year growth | 19.4% | β |
| Share count change | 2.1% | β3.8% |
| Profitability | ||
| Gross margin | 91.7% | 80.2% |
| Operating margin | 9.8% | 21.2% |
| Net margin | 36.5% | 17.0% |
| FCF margin | 9.8% | β7.5% |
| Return on capital | β | β |
| Return on equity | 39.9% | β |
| Balance sheet | ||
| Net debt | β | $124M |
| Net debt / EBITDA | β | 0.5x |
| Dividends and buybacks | $0.0M | $11.0M |
| Valuation & quality | ||
| P/E | 8.8x | 12.4x |
| Piotroski F-score | β | 4 |
FY16
ACAD $17.3M
INDV β
FY17
ACAD $125M
INDV β
FY18
ACAD $224M
INDV β
FY19
ACAD $339M
INDV β
FY20
ACAD $442M
INDV β
FY21
ACAD $484M
INDV $791M
FY22
ACAD $517M
INDV $901M
FY23
ACAD $726M
INDV $1.1B
FY24
ACAD $958M
INDV $1.2B
FY25
ACAD $1.1B
INDV $1.2B
ACAD
INDV
FY16
ACAD β1,574.1%
INDV β
FY17
ACAD β234.1%
INDV β
FY18
ACAD β110.6%
INDV β
FY19
ACAD β72.7%
INDV β
FY20
ACAD β64.9%
INDV β
FY21
ACAD β35.2%
INDV 26.9%
FY22
ACAD β43.2%
INDV β9.0%
FY23
ACAD β10.1%
INDV β13.9%
FY24
ACAD 24.1%
INDV 3.2%
FY25
ACAD 9.8%
INDV 21.2%
ACAD
INDV
FY16
ACAD β$210M
INDV β
FY17
ACAD β$219M
INDV β
FY18
ACAD β$170M
INDV β
FY19
ACAD β$152M
INDV β
FY20
ACAD β$144M
INDV β
FY21
ACAD β$127M
INDV $349M
FY22
ACAD β$114M
INDV β$9.0M
FY23
ACAD $16.7M
INDV β$308M
FY24
ACAD $157M
INDV $7.0M
FY25
ACAD $105M
INDV β$93.0M
ACAD
INDV
FY16
ACAD β
INDV β
FY17
ACAD β
INDV β
FY18
ACAD β
INDV β
FY19
ACAD β
INDV β
FY20
ACAD β
INDV β
FY21
ACAD β
INDV β
FY22
ACAD β
INDV β
FY23
ACAD β
INDV β
FY24
ACAD β
INDV β
FY25
ACAD β
INDV β
ACAD
INDV
Each company's latest fiscal year; fiscal years end in different months. The best value in each row is highlighted where higher (or lower) is clearly better. Not investment advice.